Endometrial Carcinoma
Conditions
Brief summary
Endometrial cancer, the most common gynecologic cancer worldwide, is steadily increasing in developed countries.The early-stage forms of endometrial cancer are usually highly curable by surgical treatment alone, whereas advanced stages require adjuvant interdictions such as radiotherapy and chemotherapy. Platinum and anthracycline drugs have long been used as standard adjuvant chemotherapy drugs for advanced and recurrent endometrial carcinomas. In one study, the standard combination adjuvant treatment with AP was found to be more effective as an adjuvant therapy than whole abdominal irradiation
Interventions
DRUGPaclitaxel/epirubcin/carboplatin
adjuvant treatment in endometrial carcinoma
Dose dense paclitaxel/carboplatin
Sponsors
Sohag University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
• Age group: Histologically diagnosed with primary endometrial carcinoma * more than 20 years old. * Any histological type of endometrial carcinoma * Stage III, IV * Stage one I or II with one or more of the following factors: 1. Histologic grade 3 endometroid carcinoma with myometrial invasion still within half of the myometrium 2. histological grade 1,2 endometroid carcinomas with invasion of over half of myometrium 3. cervical stromal invasion 4. vascular invasion; or 5. serous carcinoma, clear cell carcinoma, or undifferentiated carcinoma * performance status 0-2 * adequate function of all major organs
Exclusion criteria
* • Pt has received prior radiation or chemotherapy. * Pt with sarcomatous component * Metastatic endometrial carcinoma * Other malignancy * Unfit patient for chemotherapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Completion rate of chemotherapy | 6 months | 6 cycles |
Countries
Egypt
Outcome results
None listed